ZIAC® (Bisoprolol Fumarate and Hydrochlorothiazide) Tablets
ZIAC (bisoprolol fumarate and hydrochlorothiazide) is indicated for the treatment of hypertension. It combines two antihypertensive agents in a once-daily dosage: a synthetic beta1-selective (cardioselective) adrenoceptor blocking agent (bisoprolol fumarate) and a benzothiadiazine diuretic (hydrochlorothiazide).
ZIAC (bisoprolol fumarate and hydrochlorothiazide) is indicated in the management of hypertension.
Media Articles Related to Ziac (Bisoprolol / Hydrochlorothiazide)
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2013.11.25]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/25/2013 12:00:00 AM
Increased risk of alcohol-related hypertension in individuals who flush after drinking
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2013.11.21]
Excessive drinking is a known risk factor for hypertension. Drinking that results in facial flushing indicates high sensitivity or even intolerance to alcohol. A study of the relationship between drinking and these two conditions has found that drinking-related hypertension has a lower threshold value and higher risk in flushers than in non-flushers.
Some allergy suffers with hypertension may be at increased risk for severe reaction
Source: Allergy News From Medical News Today [2013.11.12]
Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple.
In low-income urban neighborhoods the rates of diabetes, hypertension, heart disease and stroke are much higher
Source: Hypertension News From Medical News Today [2013.11.07]
There is more to the cost of living in a food desert than higher prices for the few fruits and vegetables sold nearby, according to a study by an Indiana University-Purdue University Indianapolis researcher and the Marion County Public Health Department.
Further positive Opsumit (macitentan) data in pulmonary arterial hypertension presented at CHEST 2013
Source: Hypertension News From Medical News Today [2013.10.31]
Actelion (SIX: ATLN) has announced that following the recent FDA approval and positive CHMP opinion for macitentan (Opsumit®) in pulmonary arterial hypertension (PAH), further positive data on the efficacy of macitentan from the SERAPHIN study were presented at CHEST 2013 in Chicago, USA (26-31 October 2013).
Published Studies Related to Ziac (Bisoprolol / Hydrochlorothiazide)
Screening for eligibility in the study of antihypertensive medication in children: experience from the Ziac Pediatric Hypertension Study. [2001.08]
BACKGROUND: The FDA Modernization Act has resulted in an increase in pediatric trials of antihypertensive medications. As experience is limited in children to guide the planning of these studies, we reviewed data from the Ziac Pediatric Hypertension Study to determine patterns of early study termination to help future studies... CONCLUSIONS: These data suggest that SBP hypertension should be part of inclusion criteria to increase enrollment and reduce the rate of screening termination, and that 1-week placebo screening is necessary and sufficient to minimize inclusion of transiently hypertensive subjects.
Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. [2000.10]
BACKGROUND: Several studies have shown the benefits of antihypertensive treatment in elderly patients in terms of cardiovascular morbidity and mortality rate reduction. Low-dose drug combinations may be of interest in treating older subjects. A randomized, multicenter, double-blind, parallel group study was conducted to compare the efficacy and safety of bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg (n = 84) to amlodipine 5 mg (n = 80) in isolated systolic hypertension in patients older than 60 years... CONCLUSIONS: This study demonstrates comparable efficacy and tolerability of bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg and amlodipine 5 mg. The low-dose combination of bisoprolol and hydrochlorothiazide may be an appropriate alternative for elderly patients with systolic hypertension.
Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril, and placebo: combined analysis of comparative studies. [1998.09]
To assess the efficacy and safety of 2.5, 5, and 10 mg bisoprolol/6. 25 mg hydrochlorothiazide (HCTZ), 2.5, 5, and 10 mg amlodipine; and 5, 10, 20, and 40 mg enalapril in subjects (n = 541) with a sitting diastolic blood pressure of 95 to 114 mm Hg, data from two comparative studies were pooled... Lower doses of two drugs in fixed combination can provide as good or better blood pressure control compared with higher doses of a single drug with similar tolerability and safety.
Efficacy of low-dose combination of bisoprolol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension. [1998.06.01]
The efficacy of the low-dose combination of bisoprolol/hydrochlorothiazide was compared with amlodipine and enalapril. The low-dose combination was found to be at least as effective as amlodipine and more effective than enalapril in both men and women..
Low-dose bisoprolol/hydrochlorothiazide: an option in first-line, antihypertensive treatment. [1993.09]
Two recent, multicenter, double-blind, placebo-controlled studies established the efficacy and safety of low-dose bisoprolol/hydrochlorothiazide (HCTZ) in patients with mild to moderate essential hypertension. Bisoprolol, a cardioselective beta-blocker, was used in a dose of 2.5 mg, 5 mg, or 10 mg...
Clinical Trials Related to Ziac (Bisoprolol / Hydrochlorothiazide)
A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Diabetic and Hypertensive Filipinos [Recruiting]
The aim of this 12-week, multicenter, interventional, prospective, open-label and
uncontrolled study is to evaluate the safety and efficacy of 5 mg/day and 10 mg/day
bisoprolol in hypertensive and diabetic Filipino subjects as monotherapy or as an add-on
Reports of Suspected Ziac (Bisoprolol / Hydrochlorothiazide) Side Effects
Drug Ineffective (3),
Blood Pressure Inadequately Controlled (3),
Cerebrovascular Accident (3),
Skin Exfoliation (1),
Muscle Rigidity (1),
Dermatitis Psoriasiform (1),
non-Cardiogenic Pulmonary Oedema (1),
Conjunctival Hyperaemia (1),
Oedema Peripheral (1), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Ziac has an overall score of 8. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Ziac review by 51 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || high blood pressure|
|Dosage & duration:|| || 5 mg taken 1/day for the period of 2 years|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || It lowers blood pressure from 100/150 to 85/130 and it also helps eliminate excess fluids which made me very bloated. Now when I wake up in the morning my eyes are not that swollen. Also my heart seems to work without much effort. Before I felt my heart pumping hard and now I can't hardly feel it.|
|Side effects:|| || None that I can tell.|
|Comments:|| || I take 1 pill of 5 mg every night before going to bed.|
Page last updated: 2013-11-25